![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 19, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
September 30, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 23, 2021
Fall 2021 Group Meeting to be virtual; a new prevention trial; the case for COVID-19 vaccination
July 7, 2021
ECOG-ACRIN will hold its Fall 2021 Group Meeting as a face-to-face meeting for the first time in two years
May 28, 2021
Virtual Spring 2021 Group Meeting generates record attendance; screening and genomic trials return to full activity
April 27, 2021
Most of us are virtual meeting pros by now—and though many miss the connection and energy of in-person events, there is something to be said for attending sessions in sweatpants, a favorite coffee mug in hand
February 25, 2021
COVID-19 vaccination and patients with cancer; the impact of delayed screening; a virtual Spring 2021 Group Meeting
December 14, 2020
Lessons learned from our first virtual Group Meeting and a new leadership appointment
October 20, 2020
What are the elements of a productive meeting when we get together – and what might they look like in a virtual format?
October 19, 2020
The Fall 2020 Group Meeting will look different this year – a fact that should not be too surprising, given that it will take place entirely online
July 29, 2020
In the fifth month of restrictions due to COVID-19, member institutions pivot back to focus on general health care; clinical trial enrollments begin to rise back up to pre-pandemic levels; Fall 2020 Group Meeting to be virtual; EA holds first meeting of planned move to an anti-racist agenda
February 28, 2020
January meeting with NCI leaders and the Cooperative Group Chairs; Congress increases NCI and overall NIH budget for FY 2020; EA opens two new trials, one for pancreatic cyst monitoring (EA2185) and the other to evaluate nivolumab in head and neck cancer (EA3161); plans are underway for the next Comis Symposium